4-溴-2-甲基噻唑 | 298694-30-1

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-溴-2-甲基噻唑
• 中文别名: 2-甲基-4-溴噻唑
• 英文名称: 4-bromo-2-methylthiazole
• 英文别名: 4-bromo-2-methyl-1,3-thiazole；2-methyl 4-bromothiazole
• CAS: 298694-30-1
• 化学式: C₄H₄BrNS
• 分子量: 178.052
• InChiKey: LYRXILTUZBBMNS-UHFFFAOYSA-N

物化性质

• 沸点：
  199.2±13.0 °C(Predicted)
• 密度：
  1.702±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934100090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  -20°C，保存在惰性气体中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-2-methylthiazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-2-methylthiazole
CAS number: 298694-30-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H4BrNS
Molecular weight: 178.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-2-甲基噻唑 在 硫酸 、 硝酸 作用下， 反应 3.0h， 以28 g的产率得到4-bromo-2-methyl-5-nitrothiazole
  参考文献：
  名称：

  [EN] 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS
  [FR] DÉRIVÉS DE 2-(1-HÉTÉROARYLPIPÉRAZIN-4-YL)MÉTHYL-1,4-BENZODIOXANE À UTILISER N EN TANT QU'ANTAGONISTES D'ALPHA2C

  摘要：

  式I（式I）的化合物中，其中A是一个含有1、2或3个N、O或S环杂原子的可选择取代的五元不饱和杂环环，表现出α2C拮抗活性，因此对于治疗外周或中枢神经系统的疾病或症状是有用的。

  公开号：

  WO2016193551A1
• 作为产物：
  描述：

  三氟甲烷磺酸甲酯 在 正丁基锂 作用下， 以 乙醚 、 正己烷 为溶剂， 反应 1.33h， 生成 4-溴-2-甲基噻唑
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS
  [FR] COMPOSES HETEROCYCLIQUES

  摘要：

  式I的化合物及其药用盐，其中Ar和R如规范中所定义，含有这种化合物的组合物以及这种化合物和组合物在治疗中的用途。

  公开号：

  WO2003087104A1

文献信息

• [EN] COMT INHIBITORS<br/>[FR] INHIBITEURS DE COMT
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014102233A1

  公开（公告）日：2014-07-03

  The present invention relates to compounds of formula (I), wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.

  本发明涉及式(I)的化合物，其中取代基如权利要求1所述，并且其药学上可接受的盐。这些化合物抑制酶儿茶酚-O-甲基转移酶(COMT)。这些化合物可用于治疗帕金森病、抑郁症、认知障碍和运动症状、抗抑郁症、认知障碍、情绪和精神分裂症的消极症状。
• [EN] SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE<br/>[FR] PYRROLOPYRIDINES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE LA KINASE APPARENTÉE AU RÉCEPTEUR DE L'ACTIVINE
  申请人：BLUEPRINT MEDICINES CORP

  公开号：WO2019079649A1

  公开（公告）日：2019-04-25

  Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

  本文描述了抑制ALK2及其突变体的化合物，包括这些化合物的药物组合物，以及使用这些化合物和组合物的方法。
• Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties
  作者：Ganesha Rai、Daniel J. Urban、Bryan T. Mott、Xin Hu、Shyh-Ming Yang、Gloria A. Benavides、Michelle S. Johnson、Giuseppe L. Squadrito、Kyle R. Brimacombe、Tobie D. Lee、Dorian M. Cheff、Hu Zhu、Mark J. Henderson、Katherine Pohida、Gary A. Sulikowski、David M. Dranow、Md Kabir、Pranav Shah、Elias Padilha、Dingyin Tao、Yuhong Fang、Plamen P. Christov、Kwangho Kim、Somnath Jana、Pavan Muttil、Tamara Anderson、Nitesh K. Kunda、Helen J. Hathaway、Donna F. Kusewitt、Nobu Oshima、Murali Cherukuri、Douglas R. Davies、Jeffrey P. Norenberg、Larry A. Sklar、William J. Moore、Chi V. Dang、Gordon M. Stott、Leonard Neckers、Andrew J. Flint、Victor M. Darley-Usmar、Anton Simeonov、Alex G. Waterson、Ajit Jadhav、Matthew D. Hall、David J. Maloney

  DOI：10.1021/acs.jmedchem.0c00916

  日期：2020.10.8

  of compounds, using structure-based design concepts, coupled with optimization of cellular potency, in vitro drug–target residence times, and in vivo PK properties, to identify first-in-class inhibitors that demonstrate LDH inhibition in vivo. The lead compounds, named NCATS-SM1440 (43) and NCATS-SM1441 (52), possess desirable attributes for further studying the effect of in vivo LDH inhibition.

  乳酸脱氢酶（LDH）催化丙酮酸向乳酸的转化，同时还原的烟酰胺腺嘌呤二核苷酸的氧化是糖酵解途径的最后一步。糖酵解在癌细胞的代谢可塑性中起重要作用，长期以来一直被认为是潜在的治疗靶点。因此，LDH的有效的选择性抑制剂代表了一种有吸引力的治疗方法。然而，迄今为止，药理剂未能实现体内显着的靶标结合，可能是因为蛋白质以非常高的浓度存在于细胞中。我们在此报告了一项领先的优化运动，该研究使用基于结构的设计概念，重点研究了吡唑基系列化合物，并在体外优化了细胞效能药物-靶标的停留时间和体内PK特性，以鉴定可证明LDH在体内具有抑制作用的一流抑制剂。名为NCATS-SM1440（43）和NCATS-SM1441（52）的先导化合物具有进一步研究体内LDH抑制作用所需的属性。
• SERINE/THREONINE KINASE INHIBITORS
  申请人：GENENTECH, INC.

  公开号：US20150031674A1

  公开（公告）日：2015-01-29

  Compounds having the formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R a , R b , R c , R d , R e , n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

  具有公式I的化合物，其中R1、R2、R3、R4、R5、Ra、Rb、Rc、Rd、Re、n、r、s和t的定义如本文所述，并且这些化合物是PAK1的抑制剂。还公开了用于治疗癌症和过度增殖性疾病的组合物和方法。
• [EN] AZABICYCLO [3. 1. O] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS<br/>[FR] DÉRIVÉS D'AZABICYCLO[3.1.0]HEXYLE EN TANT QUE MODULATEURS DE RÉCEPTEURS DOPAMINERGIQUES D3
  申请人：GLAXO GROUP LTD

  公开号：WO2009043883A1

  公开（公告）日：2009-04-09

  The present invention relates to novel compounds of formula (I) or a salt thereof: wherein R1 is a 5-membered heteroaryl group, optionally fused with a 6-membered hetero or carbocycle; such 5 or 11-membered system, may be optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, C1-4alkanoyl, haloC1-4alkoxy and SF5, and n is 1 or 2; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.

  本发明涉及式(I)的新化合物或其盐：其中R1是一个5-成员杂芳基团，可选地与一个6-成员杂环或碳环融合；这样的5或11-成员体系，可以选择地由卤素、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、C1-4烷酰基、卤代C1-4烷氧基和SF5中的1、2、3或4个取代基取代，并且n为1或2；其制备方法，用于这些方法的中间体，含有它们的药物组合物以及它们在治疗中的用途，作为多巴胺D3受体调节剂，例如用于治疗药物依赖、作为抗精神病药物、用于治疗强迫症谱系障碍或早泄。